{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Powder",
    "query": {
      "intervention": "Placebo Powder"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 894,
    "total_pages": 90,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Powder&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-02T07:34:24.225Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01667679",
      "title": "Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Migraine",
        "Headaches"
      ],
      "interventions": [
        {
          "name": "100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally",
          "type": "DRUG"
        },
        {
          "name": "OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avanir Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 275,
      "start_date": "2012-08",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2017-04-12",
      "last_synced_at": "2026-09-02T07:34:24.225Z",
      "location_count": 13,
      "location_summary": "San Francisco, California • Santa Monica, California • Fairfied, Connecticut + 10 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Fairfied",
          "state": "Connecticut"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Watertown",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01667679"
    },
    {
      "nct_id": "NCT00489489",
      "title": "Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Teriflunomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for Teriflunomide)",
          "type": "DRUG"
        },
        {
          "name": "Interferon-β",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 118,
      "start_date": "2007-05",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2012-11-06",
      "last_synced_at": "2026-09-02T07:34:24.225Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00489489"
    },
    {
      "nct_id": "NCT02431468",
      "title": "A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Bryostatin 1",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Neurotrope Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 147,
      "start_date": "2015-11",
      "completion_date": "2017-02",
      "has_results": true,
      "last_update_posted_date": "2018-07-06",
      "last_synced_at": "2026-09-02T07:34:24.225Z",
      "location_count": 29,
      "location_summary": "Phoenix, Arizona • Costa Mesa, California • Los Alamitos, California + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlantis",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02431468"
    },
    {
      "nct_id": "NCT02819297",
      "title": "BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Constipation",
        "Chronic Idiopathic Constipation",
        "CIC"
      ],
      "interventions": [
        {
          "name": "BLI400 Laxative",
          "type": "DRUG"
        },
        {
          "name": "BLI400 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Braintree Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1020,
      "start_date": "2016-06",
      "completion_date": "2017-06",
      "has_results": true,
      "last_update_posted_date": "2020-07-27",
      "last_synced_at": "2026-09-02T07:34:24.225Z",
      "location_count": 51,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 43 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02819297"
    },
    {
      "nct_id": "NCT00499460",
      "title": "Effects of Garlic Supplements on Opioids in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Healthy, No Evidence of Disease"
      ],
      "interventions": [
        {
          "name": "garlic powder tablets",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "oxycodone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "21 Years to 45 Years"
      },
      "enrollment_count": 15,
      "start_date": "2006-11",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2017-04-07",
      "last_synced_at": "2026-09-02T07:34:24.225Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00499460"
    },
    {
      "nct_id": "NCT01119950",
      "title": "Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "NVA237 12.5 µg once daily",
          "type": "DRUG"
        },
        {
          "name": "NVA237 25.0 µg once daily",
          "type": "DRUG"
        },
        {
          "name": "NVA237 12.5 µg twice daily",
          "type": "DRUG"
        },
        {
          "name": "NVA237 50.0 µg once daily",
          "type": "DRUG"
        },
        {
          "name": "NVA237 25.0 µg twice daily",
          "type": "DRUG"
        },
        {
          "name": "NVA237 100.0 µg once daily",
          "type": "DRUG"
        },
        {
          "name": "NVA237 50.0 µg twice daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo to NVA237 once daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 388,
      "start_date": "2010-04",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2015-03-23",
      "last_synced_at": "2026-09-02T07:34:24.225Z",
      "location_count": 6,
      "location_summary": "Anniston, Alabama • San Diego, California • Torrance, California + 3 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01119950"
    },
    {
      "nct_id": "NCT02190747",
      "title": "An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fibrodysplasia Ossificans Progressiva"
      ],
      "interventions": [
        {
          "name": "Palovarotene",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Clementia Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2014-07-14",
      "completion_date": "2016-05-23",
      "has_results": true,
      "last_update_posted_date": "2021-02-16",
      "last_synced_at": "2026-09-02T07:34:24.225Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02190747"
    },
    {
      "nct_id": "NCT07706283",
      "title": "Sex-Divergent Effects of Magnesium L-Threonate Supplementation on Sleep Quality, Cognitive Performance, and Neuromuscular Function in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy Adults; Cognitive Performance; Sleep Quality; Neuromuscular Function"
      ],
      "interventions": [
        {
          "name": "Magnesium L-threonate",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Barry University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 81,
      "start_date": "2025-12-01",
      "completion_date": "2026-03-19",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-09-02T07:34:24.225Z",
      "location_count": 1,
      "location_summary": "Miami Shores, Florida",
      "locations": [
        {
          "city": "Miami Shores",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07706283"
    },
    {
      "nct_id": "NCT02972996",
      "title": "Blueberry Consumption and Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Blueberry",
          "type": "OTHER"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Albany Research Institute, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "45 Years to 75 Years · Male only"
      },
      "enrollment_count": 55,
      "start_date": "2017-01-19",
      "completion_date": "2018-06-21",
      "has_results": true,
      "last_update_posted_date": "2022-04-19",
      "last_synced_at": "2026-09-02T07:34:24.225Z",
      "location_count": 1,
      "location_summary": "Albany, New York",
      "locations": [
        {
          "city": "Albany",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02972996"
    },
    {
      "nct_id": "NCT00662779",
      "title": "Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Exercise-induced Bronchospasm"
      ],
      "interventions": [
        {
          "name": "arformoterol",
          "type": "DRUG"
        },
        {
          "name": "formoterol",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of New Mexico",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 0,
      "start_date": "2008-04",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2015-12-11",
      "last_synced_at": "2026-09-02T07:34:24.225Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00662779"
    }
  ]
}